Rituxan

Latest stories

12d
Business Wire
Biogen 2015 Revenues Increase 11% to $10.8 BillionCAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) today reported fu
Biogen 2015 Revenues Increase 11% to $10.8 Billion
Business Wire / Posted 12 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) today reported full year and fourth quarter 2015 results, including full year revenues of $10.8 billion, an 11% increase versus 2014. Full year 2015 Non-GAAP diluted earnings per share... Read more
24d
Morningstar
More High-Quality Stocks Now in Buying RangeAs we've mentioned before, the market isn't a screaming buy even after the shel
More High-Quality Stocks Now in Buying Range
Morningstar / Posted 24 days ago
As we've mentioned before, the market isn't a screaming buy even after the shellacking. Nevertheless, the turmoil this week has driven five high-quality stocks into 5-star territory. These stocks all possess wide moats, meaning that they have... Read more
28d
Business Wire
ImmunoGen Announces Recent Product Program Advancements and Anticipated 2016 Events in Advance of J.P. Morgan Healthcare Conference“ImmunoGen made significant progress in 2015 that is anticipated to lead to a n
ImmunoGen Announces Recent Product Program Advancements and Anticipated 2016 Events in Advance of J.P. Morgan Healthcare Conference
Business Wire / Posted 28 days ago
“ImmunoGen made significant progress in 2015 that is anticipated to lead to a number of meaningful events in 2016 and beyond," commented Daniel Junius, President and CEO. “For mirvetuximab soravtansine, our lead program, these include completing... Read more

People in this news